For Healthcare Professionals

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD


About the study

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  1. Lp(a) ≥ 70 mg/dL at the screening visit, measured at the Central laboratory
  2. Myocardial infarction: ≥ 3 months from screening and randomization to ≤ 10 years prior to the screening visit
  3. Ischemic stroke: ≥ 3 months from screening and randomization to ≤ 10 years prior to the screening visit
  4. Clinically significant symptomatic peripheral artery disease Key


  1. Uncontrolled hypertension
  2. Heart failure New York Heart Association (NYHA) class IV
  3. History of malignancy of any organ system
  4. History of hemorrhagic stroke or other major bleeding
  5. Platelet count ≤LLN
  6. Active liver disease or hepatic dysfunction
  7. Significant kidney disease
  8. Pregnant or nursing women Other protocol-defined inclusion/
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-888-669-6682Email iconEmail Study Center

Study’s details


Cardiovascular Disease and Lipoprotein(a)

Age (in years)

18 - 80


Phase 3

Participants needed


Est. Completion Date

May 2025

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.